Effect of Differences in Metabolic Activity of Melanoma Models on Response to Lonidamine plus Doxorubicin

Lonidamine (LND), a metabolic modulator, sensitizes DB-1 human melanoma to doxorubicin (DOX) chemotherapy by acidifying and de-energizing the tumor. This report compares the effects of LND on two human melanoma lines, DB-1 and WM983B, which exhibit different metabolic properties. Using liquid chroma...

Descripción completa

Detalles Bibliográficos
Autores principales: Nath, Kavindra, Roman, Jeffrey, Nelson, David S., Guo, Lili, Lee, Seung-Cheol, Orlovskiy, Stepan, Muriuki, Kevin, Heitjan, Daniel F., Pickup, Stephen, Leeper, Dennis B., Blair, Ian A., Putt, Mary E., Glickson, Jerry D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168452/
https://www.ncbi.nlm.nih.gov/pubmed/30279592
http://dx.doi.org/10.1038/s41598-018-33019-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168452/
https://www.ncbi.nlm.nih.gov/pubmed/30279592
http://dx.doi.org/10.1038/s41598-018-33019-4

Ejemplares similares